Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tomentosin SCHEMBL29422245 | 1.00 | KDR (0.58) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL10028473 | 0.82 | KDR (0.51) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL2553256 | 0.73 | KDR (1.00) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL29367155 | 0.73 | KDR (0.52) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL16202801 | 0.62 | LMNA (0.35) | — | |
| Carabrone SCHEMBL30046035 | 0.61 | NLRP3 (0.40) | MAPTRAB9ANPC1XBP1HTT | |
| SCHEMBL29410309 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL8629536 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL9240777 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL9242953 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | KDR 4401/4885MAPT 1720/4885RAB9A 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.